3/18
09:47 am
acad
Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences [Yahoo! Finance]
Low
Report
Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences [Yahoo! Finance]
3/17
02:27 pm
acad
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year [Yahoo! Finance]
3/15
09:34 pm
acad
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness [Yahoo! Finance]
Medium
Report
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness [Yahoo! Finance]
3/12
04:20 pm
acad
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum [Yahoo! Finance]
Medium
Report
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum [Yahoo! Finance]
3/12
04:05 pm
acad
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Medium
Report
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
3/11
03:15 pm
acad
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer's Readout Ahead [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer's Readout Ahead [Yahoo! Finance]
3/5
12:24 am
acad
Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge [Yahoo! Finance]
Medium
Report
Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge [Yahoo! Finance]
3/4
11:55 pm
acad
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? [Yahoo! Finance]
Medium
Report
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? [Yahoo! Finance]
3/4
03:56 pm
acad
ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
3/3
04:28 pm
acad
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors [Yahoo! Finance]
Medium
Report
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors [Yahoo! Finance]
3/3
04:05 pm
acad
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Medium
Report
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
3/2
09:02 pm
acad
ACADIA Pharmaceuticals (ACAD) had its "neutral" rating reaffirmed by Bank of America Corporation.
Low
Report
ACADIA Pharmaceuticals (ACAD) had its "neutral" rating reaffirmed by Bank of America Corporation.
3/2
05:54 pm
acad
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 [Yahoo! Finance]
3/2
04:05 pm
acad
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Low
Report
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
3/2
01:59 pm
acad
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains [Yahoo! Finance]
Low
Report
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains [Yahoo! Finance]
2/28
09:08 am
acad
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker [Seeking Alpha]
Medium
Report
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker [Seeking Alpha]
2/26
12:53 pm
acad
ACADIA Pharmaceuticals (ACAD) had its price target raised by TD Cowen from $35.00 to $37.00. They now have a "buy" rating on the stock.
Medium
Report
ACADIA Pharmaceuticals (ACAD) had its price target raised by TD Cowen from $35.00 to $37.00. They now have a "buy" rating on the stock.
2/26
10:30 am
acad
ACADIA Pharmaceuticals (ACAD) had its price target lowered by Royal Bank Of Canada from $31.00 to $30.00. They now have an "outperform" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (ACAD) had its price target lowered by Royal Bank Of Canada from $31.00 to $30.00. They now have an "outperform" rating on the stock.
2/26
09:55 am
acad
ACADIA Pharmaceuticals (ACAD) had its price target raised by Citizens Jmp from $34.00 to $35.00. They now have a "market outperform" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (ACAD) had its price target raised by Citizens Jmp from $34.00 to $35.00. They now have a "market outperform" rating on the stock.
2/26
09:26 am
acad
ACADIA Pharmaceuticals (ACAD) had its price target lowered by Stifel Nicolaus from $25.00 to $24.00. They now have a "hold" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (ACAD) had its price target lowered by Stifel Nicolaus from $25.00 to $24.00. They now have a "hold" rating on the stock.
2/26
12:42 am
acad
ACADIA Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/25
06:58 pm
acad
ACADIA (ACAD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
ACADIA (ACAD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
06:41 pm
acad
ACADIA Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
04:05 pm
acad
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Low
Report
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
2/25
06:24 am
acad
ACADIA Pharmaceuticals (ACAD) was upgraded by Wolfe Research to "strong-buy".
Low
Report
ACADIA Pharmaceuticals (ACAD) was upgraded by Wolfe Research to "strong-buy".